|Day's range||467.50 - 485.10|
|52-week range||464.00 - 622.50|
|PE ratio (TTM)||180.30|
|Dividend & yield||N/A (N/A)|
|1y target est||81.80|
The chief executive of AstraZeneca has said uncertainty over the regulatory regime post-Brexit meant the company would "wait to see" before taking some key decisions about further investment ...
Moody's Investors Service said on Friday it changed its outlook on AstraZeneca Plc's long-term debt rating to negative from stable, a day after the company's closely watched advanced lung cancer trial failed. Moody's said the change in outlook reflects the increased execution risk present in the company's pipeline and the negative results of the lung cancer trial. AstraZeneca's combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, triggering the biggest ever daily fall in its shares on Thursday.
AstraZeneca was Friday's outperformer after a meeting with management helped bolster confidence that investors have been too hasty to write off the drugmaker's flagship cancer treatment. Pascal Soriot, ...